Search | VHL Regional Portal

Excellent outcome of children/adolescents with primary mediastinal large B-cell lymphoma treated with FAB/LMB-based chemotherapy regimen with rituximab.

Dourthe, Marie Emilie; Auperin, Anne; Rigaud, Charlotte; Barbati, Melissa; Bonneau, Jacinthe; Buchbinder, Nimrod; Couec, Marie-Laure; Dartigues, Peggy; Ducassou, Stéphane; Garnier, Nathalie; Haouy, Stéphanie; Jonca, Bénédicte; Jourdain, Anne; Leruste, Amaury; Molina, Thierry; Montravers, Françoise; Pasquet, Marlène; Phulpin, Aurélie; Poirée, Maryline; Simonin, Mathieu; Spiegel, Alexandra; Verschuur, Arnauld; Leblanc, Thierry; Landman-Parker, Judith; Patte, Catherine; Minard-Colin, Véronique.

Haematologica ; 2024 Jul 11.

Article in English | MEDLINE | ID: mdl-38988265

ABSTRACT

Not available.

Elranatamab treatment in a multiple myeloma patient undergoing renal dialysis.

Van de Wyngaert, Zoé; Romera-Martinez, Irene; Chedeville, Céline; Musiu, Paolo; Ikhlef, Souhila; Jonca, Bénédicte; Mohty, Mohamad; Malard, Florent.

Clin Hematol Int ; 6(2): 46-50, 2024.

Article in English | MEDLINE | ID: mdl-38817306

ABSTRACT

We present the case of a dialyzed patient with relapsed IgA and lambda free light chain multiple myeloma treated with elranatamab. Despite end-stage renal impairment, the treatment with anti-B cell maturation antigen (BCMA)xCD3 bispecific antibody proved to be feasible, without unexpected side effects. Increased attention to infectious risk is crucial for these doubly fragile patients.

ABSTRACT

ABSTRACT

SEND TO:

SELECTION OF CITATIONS

SEARCH DETAIL